Beta Bionics, Inc. Cash Flow Statement
BBNX / Health Care|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Beta Bionics, Inc. used $51M in operating cash flow and negative free cash flow of $56M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$73.2M | -$54.8M | -$44.1M |
| Depreciation & Amortization | - | $1.2M | $1.2M |
| Operating Cash Flow | -$50.9M | -$48.3M | -$32.4M |
| Capital Expenditures | $5.3M | $3.4M | $402.0K |
| Free Cash Flow | -$56.2M | -$51.7M | -$32.8M |
| FCF Margin | -56.1% | -79.3% | - |